文献速递血栓与止血

氨甲环酸联合凝血因子VIII在重型血友病A预防治疗中的止血效果:临床前研究

Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study.
PubMed 文献 · J Thromb Haemost · 2019-12-22

该临床前研究在体外和FVIII敲除小鼠中探讨氨甲环酸(TXA)联合低浓度FVIII能否改善止血。体外实验显示TXA不增强凝血酶生成但可正常化ROTEM-tPA并减小纤维蛋白直径;小鼠模型中TXA联合FVIII显著减少膝关节出血。结果提示TXA与FVIII联用于预防治疗可能有潜在获益。

要点

  • TXA不改变凝血酶生成能力,但可正常化ROTEM-tPA并增强纤维蛋白网络。

核心结论

  • 在预防治疗场景下,TXA与FVIII联用可能带来潜在止血获益。

研究设计与样本

  • 体外研究使用重型血友病A成人血样,调整FVIII终浓度为0、3、10和30 IU/dL,加或不加TXA 0.1 mg/mL。
  • 动物实验使用FVIII敲除小鼠,预防性给予FVIII 3 IU/dL或FVIII 3 IU/dL + TXA 0.1 mg/mL。
  • 体外检测包括ROTEM-tPA、凝血酶生成试验和扫描电镜;动物评估包括磁共振成像、组织学分析和尾夹实验。

主要发现

  • TXA对凝血酶生成能力无影响,符合预期。
  • TXA + rFVIII组纤维蛋白纤维直径较单用rFVIII显著减小,提示纤维蛋白网络更强。
  • 单用TXA即可使ROTEM-tPA结果正常化。

临床怎么用

  • 在重型血友病A预防治疗中,可考虑将TXA与FVIII联用以增强止血效果。
  • 联用TXA可能有助于减少关节出血,但需进一步临床研究验证。

局限性

  • 本研究为临床前研究,结果需在临床环境中验证。
  • 尾夹出血量差异未达统计学显著性,需更大样本或更敏感指标确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hemophilia is characterized by a compromised hemostatic response with delayed development of a clot and the formation of clots that are vulnerable to fibrinolysis. We proposed to study, in vitro and in factor VIII knockout mice (FVIII-KO), whether hemostasis is improved with the addition of tranexamic acid (TXA) to low FVIII plasma concentrations. METHODS: In vitro, blood samples from adults with severe hemophilia-A, spiked to final concentrations of 0-3-10 and 30IU.dL-1 of FVIII, were studied with and without TXA 0.1 mg/mL using thromboelastography in the presence of tPA (ROTEM-tPA), thrombin generation (TG) assay, and scanning electron microscopy. FVIII-KO mice received prophylaxis before trauma, to obtain circulating plasma FVIII at 3 IU.dL-1 or FVIII 3IU.dL-1 + TXA 0.1 mg/mL. After trauma-induced knee joint bleeding, magnetic resonance imaging, histological analysis, and tail clip assay were used to compare hemostastic efficacy of the two prophylactic strategies. RESULTS: A dose-dependent improvement of TG was observed with recombinant FVIII (rFVIII) alone (P = .024). As expected, no effect of TXA on TG capacity was observed. Fibrin fiber diameters were significantly decreased with TXA + rFVIII compared to rFVIII, suggesting a stronger fibrin network. Surprisingly, ROTEM-tPA was normalized with TXA alone. In FVIII-KO mice, blood loss after tail clip was lower after prophylaxis with rFVIII + TXA compared to rFVIII, with no statistical significance (P = .15). However, MRI results and histological analysis of knee joints showed that the addition of TXA significantly decreased joint bleeding (P = .022). CONCLUSION: Our results suggest a potential benefit of TXA when used in combination with FVIII in prophylactic settings.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Janbain M, Enjolras N, Bordet JC, et al. Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study. J Thromb Haemost. 2019. PMID: 31782901. doi:10.1111/jth.14694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。